...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Presentations & Events

Ho hum:

"Hello xxx,

Thank you for your question. Yes, both Resverlogix and Zenith expect to participate in scientific and/or industry conferences this year. I do not have lists of conferences that are under consideration to share with you.

Best regards,

Chris"

Share
New Message
Please login to post a reply